Trial Profile
A randomized, open-label study designed to assess persistence on treatment in women with post-menopausal osteoporosis receiving once monthly Bonviva with a patient support program, versus once weekly alendronate.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Mar 2010
Price :
$35
*
At a glance
- Drugs Alendronic acid (Primary) ; Ibandronic acid (Primary)
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- Sponsors Roche
- 04 Mar 2010 New trial record